Although the majority of patients with diabetes are undergoing background statin therapy, which may mask potential adverse effects of PCSK9 inhibitors on glycaemic control, current data suggest that the benefits outweigh the risks for diabetic patients using PCSK9 inhibitors. Considering the different nature of genetic studies and of clinical trials, close monitoring of glucose parameters is necessary, especially in individuals with prediabetes.
Keyphrases
- clinical trial
- type diabetes
- cardiovascular disease
- low density lipoprotein
- human health
- genome wide
- randomized controlled trial
- emergency department
- stem cells
- risk assessment
- mesenchymal stem cells
- metabolic syndrome
- electronic health record
- blood glucose
- copy number
- bone marrow
- adipose tissue
- insulin resistance
- skeletal muscle
- dna methylation
- artificial intelligence
- obstructive sleep apnea
- phase iii